Long-term follow-up of ocrelizumab for primary progressive multiple sclerosis in the ORATORIO trial


  • Earlier and continuous treatment with ocrelizumab can provide long-term benefits on measures of disease progression in patients with primary progressive multiple sclerosis.

Why this matters

  • Patients with multiple sclerosis currently have limited treatment options available to prevent long-term disability progression.

  • The ongoing open-label extension of the ORATORIO study provides long-term safety and efficacy data over 6.5-years of follow-up. Treatment with ocrelizumab continues to show greater benefits on measures of disease progression in comparison to placebo treatment.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.